Thompson recombination

Several areas are receiving much of the research attention. Approaches that integrate product recovery with the fermentation in a three-phase fluidized bed bioreactor reflect general research trends in biochemical engineering (Yabannavar and Wang, 1991 Davison and Thompson, 1992). The successful use of three-phase biofluidization has also been demonstrated for recombinant protein systems, where it may have some benefit in improving plasmid stability (Shu and Yang, 1996). 

Maksay, G., Thompson, S. A., and Wafford, K. A. (2000) Allosteric modulators affect the efficacy of partial agonists for recombinant GABA(A) receptors. Br. J. Pharmacol. 129, 1794-1800. 

Ebert, B., Thompson, S. A., Suonatsou, K McKeman, R., Krogsgaard-Larsen, R, and Waf-ford, K. A. (1997) Differences in agonist/antagonist binding affinity and receptor transduction using recombinant human y-aminobutyric acid type A receptors. Mol. Pharmacol. 52, 1150-1156. 

Song, S., M. Scott-Jorgensen, I Wang, A. Poirier, I Crawford, M. Campbell-Thompson, and T. Flotte, Intramuscular administration of recombinant adeno-associated virus 2 alpha-I antitrypsin (rAAV-SERPINAl) vectors in a nonhuman primate model safety and immunologic aspects. Mol Ther, 2002. 6(3) 329. 

W.-G. Hu, H.G. Thompson, A.Z. Alvi, L.P. Nagata, M.R. Suresh and R.E. Fulton, Development of immunofiltration assay by light addressable potentiometric sensor with genetically biotinylated recombinant antibody for rapid identification of Venezuelan equine encephalitis virus, J. Immunol. Methods, 289(1-2) (2004) 27-35. 

Macaloney, G. Hall, J.W. Rollins, M.J. Draper, I. Anderson, K.B. Preston, J. Thompson, B.G. McNeil, B., The utility and performance of near-infrared spectroscopy in simultaneous monitoring of multiple components in a high cell density recombinant Escherichia coli production process Bioprocess Eng. 1997, 17, 157-167. 

H.P. Schnebli, R.C. Thompson, and R.G. Crystal. 1990. Aerosolization of recombinant SLPI to augment antineutrophil elastase protection of pulmonary epithelium. /. Appl. Physiol. 69 1843-1848. 

Nick, R.C. Thompson, S.P. Eisenberg, and H. Schnebli. 1990. Pharmacokinetics and distribution of recombinant secretory leukocyte proteinase inhibitor in rats. Am. Rev. Respir. Dis. 141 889-894. 

Miao, C. H., Nakai, H., Thompson, A. R., Storm, T. A., Chiu, W., Snyder, R. O. and Kay, M. A. (2000). Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo Cell cycling does not influence hepatocyte transduction. J. Virol. 74, 3793-3803. 

Ponnazhagan, S., Mahendra, G., Kumar, S., Thompson, J. A. and Castillas, M., Jr. (2002). Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands. J. Virol. 76, 12900-12907. 

Poirier, A., Campbell-Thompson, M., Tang, Q., Scott-Jorgensen, M., Combee, L., Loiler, S., Crawford, J., Song, S. and Flotte, T. R. (2004). Toxicology and biodistribution studies of a recombinant adeno-associated virus 2-alpha-l antitrypsin vector. Preclinica 2, 43-51. 

E. C. Luccy, P. J. Stone. D. EL Ciccolclla, R. Bcuer, T. 0. Christensen, R. C. Thompson, and G- L. Snider. Recombinant human secretory leukocyte-protease inhibitor in vitro properties, and amelioration of human neutrophil elastase-induced emphysema and secretory cell metaplasia in the hamster. /. Lab. Clin. hied. 7/5 224... 

SOL A. Cast. W. Anderson, A. Probst, H. Nick, R. C. Thompson, S. P. Eisenbeig, and H. p, SchneblL Pharmacokinetics and distribution of recombinant secretory leukocyte... 

Functional Proteomics Methods and Protocols, edited by Julie D. Thompson, Christine Schaeffer-Reiss, and Marius Ueffing, 2008 483. Recombinant Proteins From Plants Methods and Protocols, edited by Loic Faye and Veromque Gomord, 2008... 

Thompson, J. F., Landy, A. (1988) Empirical Estimation of Protein-Induced DNA Bending Angles Application to Lambda Site-Specific Recombination Complexes, Nucleic Acids Res. 16, 9687-9707. 

Bovill EG, Tracy RP, Knatterud GL, Stone PH, Nasmith J, Gore JM, Thompson BW, Toiler GH, Kleiman NS, Cannon C, Braunwald E. Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIB trial). Am J Cardiol 1997 79(4) 391-6. 

Thompson JA, CoxWW, Lindgren CG, Collins C, Neraas KA, Bonnem EM, Fefer A Subcutaneous recombinant gamma interferon in cancer patients toxicity, pharmacokinetics, and immunomodulatory effects, Cancer Immunol Immunother 1987,25 47-53... 

Arend, W.P., We%us, H.G., Thompson, R.C. and Eisenberg, S.P. (1990). Biolc cal properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J. Clin. Invest. 85, 1654-1702. 

Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, Nagy D, Gown AM, Winther B, Meuse L, Cohen LK, Thompson AR, Kay MA. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997 16 270-276. 

Thompson, J. F. Landy, A. Empirical estimation of protein-induced DNA bending angles application to site-specific recombination complexes. Nuc. Acids Res. 1988 16 9687-9705. 

Another feature common to all hexoses is their fragmentation to trioses and related products (such as lactic acid, l-hydroxy-2-propanone, and pyruvaldehyde). l-Hydroxy-2-propanone is formed by heating a solution of D-fructose in potassium acid phosphate buffer solution of pH 6.7 it was proposed that an intermediary 3,4-enediol (s) rearranges to a /3-diketone, which yields (t) by fragmentation of the molecule. Studies by Wolfrom and Schumacher and by Blair and Sowden showed that this mechanism, followed by recombination and aldolization, accounts for some of the observed products. The identification of L-a 2/io-hexulose and DL-a yZo-hexulose was conclusive in this respect, but deuterium studies by Sowden and Thompson proved the minor role of this recombination mechanism in the transformations. 

Thompson JA, Cox WW, Lindgren CG, Collins C, Neras KA, Bonnem EM, Fefer A. Subcutaneous recombinant y interferon in cancer patients toxicity, pharmacokinetics, and immunomodulatory effects. Cancer Immunol Immunother 1987 25 47-53. Sridkandan K, Garner P, Watkinson K, Pettingale K, Brinkley D, Caiman F, Tee D. A toxicity study of recombinant interferon-y given by intravenous infusion to patients with advanced cancer. Cancer Chemother Pharmacol 1986 18 63-68. 

Kass E, Schlom J, Thompson J, Guadagni F, Graziano P, Greiner JW. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res 1999 59 676-683. 

Parsons, I. C., Everett, J. R., Pacey, M. S., Ruddock, J. C., Swanson, A. G., and Thompson, C. M. (1999). Structural elucidation of a novel erythromycin, 13-cyclopentyl-13-desethyl erythromycin B, from a recombinant Saccharopolyspom erythreaea strain, NRRL 2338pIG/l. J. Antibiot. 52, 190-192. 

From this data, an exponent value of n = -2.9 1.2 is obtained. A singlecollision model for neutral-assisted three-body recombination based on the work of Thompson [36] suggests a temperature behaviour of T . A later modification of this theory by Bates [40] also predicts this numerical dependence, as does the diffusion of electron energy in energy space model of Pitaevskii [39]. Within the experimental uncertainty, excellent agreement between experiment and theory is obtained. 

---